At the Intersection of Technology and Science
Combining technology capabilities and scientific expertise comprehensively across assets, we are able to optimize outcomes, de-risk programs, and propel development and commercialization of new potential therapies.
Our in-house technology platforms deliver data-driven insights from discovery and R&D to clinical trials and commercialization.
Sumitovant is an innovation growth engine. Our preclinical, clinical, and commercial programs span numerous modalities and indications addressing unmet patient needs.
We deliver data-driven insights utilizing machine learning, computing, AI, and other technologies.
Unique Tech Platforms and Life-Sciences Expertise
Accelerated by our in-house technology platforms Digital Innovation and DrugOME™, our ACES team aims to advance patient-first programs to deliver novel and diverse therapies to address patient need in areas where treatment options are limited or non-existent.
A computational ecosystem enabling strategic analyses to inform the complete picture of a treatment’s potential, identifying clinical risks and costs, and selecting an indication – from clinical strategy to development and execution of commercial efforts.
A custom-built, cloud-based, proprietary platform for managing data at huge scales, building machine learning models and custom apps to optimize business workflow and drive valuable insights at every level of operations, supporting strategic decision making in rapid, iterative manner across Sumitovant’s portfolio.
The Advanced Comprehensive Execution and Strategy (ACES) team is responsible for monitoring, synthesizing, and interpreting the scientific literature and using this information to make better drug development decisions. The ACES team provides guidance and due diligence to our drug development teams on medicine and pharmacology, CMC (chemistry, manufacturing, and control), clinical trial design and operations, and regulatory approval processes.